Immune recovery-related patterns of post kala-azar dermal and ocular leishmaniasis in people living with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
19
7
2022
medline:
1
10
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Post kala-azar dermal leishmaniasis (PKDL) is a rare complication of visceral leishmaniasis. We aimed at reporting PKDL cases in people living with HIV (PLHIV) and compare their characteristics based on whether PKDL occurred in the context of immune recovery under antiretroviral therapy (ART) or not. National survey and literature review. We called for observations in France in October 2020 and performed a literature review from PubMed (Medline) and Web of Science up to December 2020. Two groups of patients were defined based on whether PKDL occurred in the context of immune recovery under ART (group 1) or not (group 2), and compared. Three PLHIV with PKDL identified in France in the last decade were described and added to 33 cases from the literature. Compared with group 2 (16/36, 44.4%), patients from group 1 (20/36, 55.6%) originated more frequently from Europe (12/20, 60% vs. 2/16, 12.5%; P = 0.0038), had higher median blood CD4 + cell counts (221/μl vs. 61/μl; P = 0.0005) and increase under ART (122/μl, interquartile range 73-243 vs. 33/μl, interquartile range 0-53; P = 0.0044), had less frequently concomitant visceral leishmaniasis (3/20, 15% vs. 8/12, 66.7%; P = 0.006), and a trend to more frequent ocular involvement (7/20, 35% vs. 1/16, 6.25%; P = 0.0531). In PLHIV, PKDL occurs after a cured episode of visceral leishmaniasis as part of an immune restoration disease under ART, or concomitant to a visceral leishmaniasis relapse in a context of AIDS. For the latter, the denomination 'disseminated cutaneous lesions associated with visceral leishmaniasis' seems more accurate than PKDL.
Identifiants
pubmed: 35848585
doi: 10.1097/QAD.0000000000003336
pii: 00002030-202211010-00009
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1819-1827Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zijlstra EE, Musa AM, Khalil EAG, el-Hassan IM, el-Hassan AM. Postkala-azar dermal leishmaniasis . Lancet Infect Dis 2003; 3:87–98.
el Hassan AM, Khalil EA, el Sheikh EA, Zijlstra EE, Osman A, Ibrahim ME. Post kala-azar ocular leishmaniasis . Trans R Soc Trop Med Hyg 1998; 92:177–179.
Roustan G, Jiménez JA, Gutiérrez-Solar B, Gallego JL, Alvar J, Patrón M. Postkala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B . Br J Dermatol 1998; 138:526–528.
Zijlstra EE. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses . PLoS Negl Trop Dis 2014; 8:e3258.
Zijlstra EE. The immunology of postkala-azar dermal leishmaniasis (PKDL) . Parasit Vectors 2016; 9:464.
Antinori S, Longhi E, Bestetti G, Piolini R, Acquaviva V, Foschi A, et al. Postkala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome . Br J Dermatol 2007; 157:1032–1036.
WHO. The post Kala-azar dermal leishmaniasis (PKDL) Atlas . n.d.; Geneva, Switzerland: WHO, Available at: http://www.who.int/leishmaniasis/resources/9789241504102/en/ . [Accessed 15 September 2020].
Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome . Trans R Soc Trop Med Hyg 2001; 95:668–672.
Rios-Buceta L, Buezo GF, Peñas PF, Dauden-Tello E, Aragües-Montañes M, Fraga-Fernandez J, et al. Postkala-azar dermal Leishmaniasis in an HIV-patient . Int J Dermatol 1996; 35:303–304.
Ridolfo AL, Gervasoni C, Antinori S, Pizzuto M, Santambrogio S, Trabattoni D, et al. Postkala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum . J Infect 2000; 40:199–202.
Gilad J, Borer A, Hallel-Halevy D, Riesenberg K, Alkan M, Schlaeffer F. Postkala-azar dermal leishmaniasis manifesting after initiation of highly active antiretroviral therapy in a patient with human immunodeficiency virus infection . Isr Med Assoc J 2001; 3:451–452.
Boumis E, Chinello P, Della Rocca C, Paglia MG, Proietti MF, Petrosillo N. Atypical disseminated leishmaniasis resembling postkala-azar dermal leishmaniasis in an HIV-infected patient . Int J STD AIDS 2006; 17:351–353.
Belay AD, Asafa Y, Mesure J, Davidson RN. Successful miltefosine treatment of postkala-azar dermal leishmaniasis occurring during antiretroviral therapy . Ann Trop Med Parasitol 2006; 100:223–227.
Stark D, Pett S, Marriott D, Harkness J. Postkala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient . J Clin Microbiol 2006; 44:1178–1180.
Catorze G, Alberto J, Afonso A, Vieira R, Cortes S, Campino L. Leishmania infantum /HIV co-infection: cutaneous lesions following treatment of visceral leishmaniasis . Ann Dermatol Venereol 2006; 133:39–42.
Guffanti M, Gaiera G, Bossolasco S, Ceserani N, Ratti D, Cinque P, et al. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine . Am J Trop Med Hyg 2008; 79:715–718.
Ramos A, Cruz I, Muñez E, Salas C, Fernández A, Alvarez-Espejo T. Postkala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient . Infection 2008; 36:184–186.
Tadesse A, Hurissa Z. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of antiretroviral therapy (ART) . Ethiop Med J 2009; 47:77–79.
Antunes J, da Costa JB, Guimarães M, Vaz-Pinto I, Soares-Almeida L, Filipe P. Post-Kala-azar dermal leishmaniasis due to Leishmania donovani in Europe – case report . Int J Dermatol 2013; 52:1584–1586.
Ramesh V, Avishek K, Salotra P. Postkala-azar dermal leishmaniasis in HIV-coinfected individuals: problems in diagnosis and treatment . Int J Dermatol 2015; 54:116–120.
Celesia BM, Cacopardo B, Massimino D, Gussio M, Tosto S, Nunnari G, et al. Atypical presentation of PKDL due to Leishmania infantum in an HIV-infected patient with relapsing visceral leishmaniasis . Case Rep Infect Dis 2014; 2014:370286.
Couture S, Agrawal R, Woods K, Lockwood D, Pavesio CE, Addison PKF. A case of panuveitis with hypopyon due to presumed ocular leishmaniasis in a HIV patient . J Ophthalmic Inflamm Infect 2014; 4:21.
Barroso DH, Silva CEF, Perdigao e Vasconcelos ACD, de Morais Cavalcanti SM, de Brito MEF, Medeiros ACR. Postkala-azar dermal Leishmaniasis in two different clinical contexts . An Bras Dermatol 2015; 90:108–110.
Elliott T, Simpson J, Naresh KN, Lockwood D, Bailey AC. An unusual case of postkala-azar dermal leishmaniasis in a patient with HIV and visceral leishmaniasis co-infection . Int J STD AIDS 2019; 30:1221–1223.
Abongomera C, Battaglioli T, Adera C, Ritmeijer K. Severe postkala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient . Int J Infect Dis 2019; 81:221–224.
Nandy A, Addy M, Maji AK, Guha SK. Impact of a co-factor on the dynamics of Leishmania donovani infection: does HIV infection encourage the recurrence of visceral leishmaniasis following postkala-azar dermal leishmaniasis? . Ann Trop Med Parasitol 2004; 98:651–654.
Farooq U, Choudhary S, Chacon AH, Lebrun E, Shiman MI, Hernandez J, et al. Postkala-azar dermal leishmaniasis in HIV-infected patients with AIDS: a report of two cases diagnosed in the USA . Int J Dermatol 2013; 52:1098–1104.
Bittencourt A, Silva N, Straatmann A, Nunes VLC, Follador I, Badaró R. Postkala-azar dermal leishmaniasis associated with AIDS . Braz J Infect Dis 2002; 6:313–316.
Bittencourt A, Silva N, Straatmann A, Nunes VLC, Follador I, Badaró R. Postkala-azar dermal leishmaniasis associated with AIDS . Braz J Infect Dis 2003; 7:229–233.
Rihl M, Stoll M, Ulbricht K, Bange F-C, Schmidt R-E. Successful treatment of postkala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe . J Infect 2006; 53:e25–27.
Roselino AM, Chociay MF, Costa RS, Machado AA, de Castro Figueiredo FL. L. (L.) chagasi in AIDS and visceral leishmaniasis (kala-azar) co-infection . Rev Inst Med Trop Sao Paulo 2008; 50:251–254.
Carnaúba D, Konishi CT, Petri V, Martinez ICP, Shimizu L, Pereira-Chioccola VL. Atypical disseminated leishmaniasis similar to postkala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania (Leishmania) infantum chagasi: a case report . Int J Infect Dis 2009; 13:e504–507.
Das VNR, Pandey K, Verma N, Bimal S, Lal CS, Singh D, et al. Postkala-azar dermal leishmaniasis (PKDL), HIV and pulmonary tuberculosis . Natl Med J India 2010; 23:88–89.
Shah S, Shah A, Prajapati S, Bilimoria F. Postkala-azar dermal leishmaniasis in HIV-positive patients: a study of two cases . Indian J Sex Transm Dis AIDS 2010; 31:42–44.
Gelanew T, Amogne W, Abebe T, Kuhls K, Hailu A, Schönian G. A clinical isolate of Leishmania donovani with ITS1 sequence polymorphism as a cause of para-kala-azar dermal leishmaniasis in an Ethiopian human immunodeficiency virus-positive patient on highly active antiretroviral therapy . Br J Dermatol 2010; 163:870–874.
Gelanew T, Hurissa Z, Diro E, Kassahun A, Kuhls K, Schönian G, et al. Disseminated cutaneous leishmaniasis resembling postkala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia . Am J Trop Med Hyg 2011; 84:906–912.
Pradhan A, Basak S, Chowdhury T, Mohanta A, Chatterjee A. Keratitis after post-kala-azar dermal leishmaniasis . Cornea 2018; 37:113–115.
Khalil EAG, Musa AM, Younis BM, Elfaki MEE, Zijlstra EE, Elhassan AM. Blindness following visceral leishmaniasis: a neglected postkala-azar complication . Trop Doct 2011; 41:139–140.
Pandey K, Pal B, Topno RK, Lal CS, Das VNR, Das P. Acute uveitis: a rare adverse effect of miltefosine in the treatment of postkala-azar dermal leishmaniasis . Rev Soc Bras Med Trop 2020; 54:e20200208.
Kusumesh R, Ambasta A, Arya LK, Mohan N, Sinha BP, Ravidas V. Keratitis occurring in patients treated with miltefosine for postkala-azar dermal leishmaniasis . Br J Ophthalmol 2021; 105:1497–1503.
Saurabh S, Mahabir M. Adverse ocular events on miltefosine treatment for postkala-azar dermal leishmaniasis in India . Trop Doct 2020; 50:37–42.
Rathi SK, Pandhi RK, Khanna N, Chopra P. Mucosal and peri-orificial involvement in postkala-azar dermal leishmaniasis . Indian J Dermatol Venereol Leprol 2004; 70:280–282.
Lukeš J, Mauricio IL, Schönian G, Dujardin J-C, Soteriadou K, Dedet J-P, et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy . Proc Natl Acad Sci USA 2007; 104:9375–9380.
Ramesh V, Ramam M. Histopathology of post kala-azar dermal leishmaniasis . Indian J Dermatol 2020; 65:461–464.
Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, Moller T, et al. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile . J Pathol 1999; 189:615–622.
Rabi Das VN, Siddiqui NA, Pal B, Lal CS, Verma N, Kumar A, et al. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL) . PLoS One 2017; 12:e0174497.
Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, et al. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India . PLoS Negl Trop Dis 2015; 9:e0004093.
Ghosh S, Das NK, Mukherjee S, Mukhopadhyay D, Barbhuiya JN, Hazra A, et al. Inadequacy of 12-week miltefosine treatment for Indian post-kala-azar dermal leishmaniasis . Am J Trop Med Hyg 2015; 93:767–769.
Ramesh V, Dixit KK, Sharma N, Singh R, Salotra P. Assessing the efficacy and safety of liposomal amphotericin B and miltefosine in combination for treatment of post kala-azar dermal leishmaniasis . J Infect Dis 2020; 221:608–617.
WHO Expert Committee on the Control of the Leishmaniases & World Health Organization. (2010). Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 22–26 March 2010. World Health Organization. Available at https://apps.who.int/iris/handle/10665/44412
Rutte EAL, Zijlstra EE, de Vlas SJ. Post-kala-azar dermal leishmaniasis as a reservoir for visceral leishmaniasis transmission . Trends Parasitol 2019; 35:590–592.
Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et al. Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies . Clin Infect Dis 2019; 69:251–258.
Martin-Blondel G, Mars LT, Liblau RS. Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients . Curr Opin Infect Dis 2012; 25:312–320.
Bell LCK, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis . Int J Infect Dis 2015; 32:39–45.